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Medications in the kidney 
Summary 
 Patients with chronic kidney disease constitute a population at high risk for adverse drug 
reactions and/or drug-drug-interactions. Renal dysfunction-induced pathophysiological changes 
may alter both medication pharmacodynamics and handling. Most pharmacokinetic parameters 
are adversely affected by impaired kidney function, among which reduced glomerular filtration 
and altered tubular secretion and reabsorption lead to the most specific alterations. Dosages of 
drugs cleared by the kidney should usually be adjusted according to creatinine clearance. 
Recommended methods for maintenance dosing adjustments are dose reductions, lengthening 
the dosing interval, or both. Appropriate drug selection and dosing in patients with chronic 




 Les patients avec une insuffisance rénale chronique représentent une population à haut 
risque vis-à-vis des manifestations indésirables et/ou des interactions médicamenteuses. Les 
modifications physiopathologiques associées à une altération de la fonction rénale peuvent 
altérer à la fois la pharmacodynamie et la pharmacocinétique de nombreux médicaments. La 
plupart des paramètres pharmacocinétiques sont modifiés en présence d’une insuffisance rénale, 
parmi lesquels la diminution de la filtration glomérulaire et une altération de la sécrétion et de la 
réabsorption tubulaire conduisent aux altérations les plus spécifiques. Les dosages des 
médicaments éliminés par le rein doivent généralement être ajustés en fonction de la clairance de 
la créatinine. Les méthodes habituellement recommandées pour ajuster les doses de maintenance 
sont la diminution posologique de chaque dose administrée, l’augmentation de l’intervalle entre 
deux doses successives ou une combinaison des deux. Une sélection judicieuse des médicaments 
et un ajustement approprié de leur dosage sont indispensables pour éviter les manifestations 
indésirables et garantir le meilleur pronostic des patients avec insuffisance rénale.  
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1) Introduction 
  People with chronic kidney disease (CKD) often live with many illnesses and complex 
drug treatment regimens. It is of common knowledge, since several decades, that renal function 
can modify the relationship between drug dose and clinical effect in a variety of ways (1,2). The 
effects of CKD on both pharmacokinetics (drug absorption, distribution, metabolism and 
elimination) and pharmacodynamics (drug’s effect at the target site) increase the potential for 
adverse drug reactions and drug toxicity. Indeed, renal insufficiency has been associated with an 
increased risk of adverse effects with many classes of medications (3). The risk of some, but not 
all, adverse effects has been linked to the patient’s degree of residual renal function. This may be 
the result of inappropriate individualization of those agents that are primarily eliminated by the 
kidney, or an alteration in the pharmacodynamic responses as a result of renal insufficiency (4). 
One aspect of renal excretion that is often overlooked is the elimination of biologically active or 
toxic metabolites of parent compounds.  
 Physicians managing patients with CKD are faced with difficult decisions about starting 
or continuing treatment with drugs that are handled by, or potentially toxic to, the kidney (5). 
Inappropriate dosing in patients with CKD can cause toxicity or ineffective therapy (6). In 
particular, older patients, an increasingly prevalent population, are at higher risk of development 
advanced disease and related adverse events caused by age-related decline in renal function and 
the use of multiple medications to treat comorbid conditions (7,8). Since renal function can affect 
drug disposition by a wide variety of mechanisms, the astute clinician must be aware of these 
potential mechanisms to make best use of his/her clinical skills and laboratory armamentarium 
for the patient’s benefit (9,10). In the present review, we do not aim to give detailed guidance on 
every drug, but rather to highlight general principles of drug handling by the kidney and give 
advice for drug therapy in patients with CKD. 
 
2) Role of the kidney in drug elimination 
 Almost all pharmacokinetic parameters could be adversely affected by CKD, including 
drug oral absorption and bioavailability, protein binding and distribution volume, nonrenal 
clearance (metabolism) and renal elimination (6,11). For instance, drug distribution may be 
altered in renal insufficiency due to pH-dependent protein binding and reduced protein (primarily 
albumin) levels. Interestingly, renal disease may also affect hepatic metabolism, although the 
exact underlying mechanisms are not well understood (9). All these changes could potentially 
require appropriate drug dosing in CKD patients. Here we will only focus on the role of the 
kidney in drug elimination because the most important pharmacokinetic change in CKD is 
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excretion. Renal excretion of drugs occurs through glomerular filtration and tubular secretion 
and reabsorption (12). It is influenced by renal blood flow, glomerular filtration rate (GFR) 
and urinary flow rate (11). CKD can affect glomerular blood flow and filtration, tubular 
secretion and reabsorption, as well as renal bioactivation and metabolism. Glomerular 
filtration and tubular process may both be affected in CKD, but not to the same extent, and the 
type of renal disease may differentially affect filtration and excretion (9). Methods that 
measure all renal handling pathways would allow informed dosage individualisation using an 
understanding of renal excretion pathways and patient characteristics (13).   
   
 a) Glomerular filtration 
 Drug elimination is highly dependent on prevailing level of kidney function. Therefore 
measurement (or accurate estimation) of GFR is crucial to appropriate drug dosing. The 
glomerular elimination of drugs depends on several factors, including the molecular weight 
and protein binding characteristics of the medication. Drugs bound to albumin are not filtered. 
Therefore, the filtration rate of these drugs is directly proportional to their free plasma 
concentrations, ie the fraction of the drug that actually gets filtered. In CKD, medication 
elimination by glomerular filtration is decreased, resulting in a prolonged free drug 
elimination half-life (6).  It is a well-known principle that endogenous creatinine clearance 
correlates well with the renal elimination of most medications. However, it is a common 
oversight for health care practitioners to fail to take estimates of creatinine clearance into 
account before dosing medications. The lack of dose adjustments in patients with renal 
insufficiency is an often overlooked, yet preventable, cause of drug dosing errors (see below) 
(6). Although the most practical and commonly used clinical measure of renal function is 
estimated creatinine clearance as a marker for glomerular filtration, it is noteworthy that this 
simple marker may be misleading in two important at-risk populations, neonates and the 
elderly (9). Finally, using estimated creatinine clearance as the lone measure of medication 
handling and then only adjusting those medications that are filtered by the kidney during 
CKD may be inappropriate, because several other factors could also play an important role in 
establishing an appropriate dosing regimen (6,13). 
  
 b) Tubular secretion 
 As the kidney plays an important role in the elimination of numerous endobiotics and 
xenobiotics, renal tubular epithelial cells express a variety of transporter proteins with diverse 
substrate specificities (14). Such transporters are predominantly localized to the proximal 
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tubules and utilize ATP or transmembrane ion gradients to drive the vectorial movements of 
substrate compounds. Thus, the renal proximal tubule is the primary site of carrier-mediated 
drug transport from blood to urine. Based on their preferential substrate selectivity, the renal 
transport systems have often been classified as either organic anion (OAT) or cation (OCT) 
transport systems. Many renal transporter proteins, including those for organic ions, peptides, 
and nucleosides, have been shown to directly transport or interact with a number of clinically 
utilized drugs. Focused studies of drug transporters in the kidney have significantly enhanced 
our understanding of the cellular and molecular basis of transporter-mediated drug elimination 
(14). 
 Although protein binding decreases the glomerular filtration of some drugs, the renal 
tubular secretion of these medications may be increased. Indeed, highly protein-bound 
medications are actively secreted into the proximal convoluted tubules, ensuring they are 
excreted via transporters (14). However, with advanced kidney disease, drug clearance is 
significantly impaired despite tubular secretion. Indeed, in CKD, the secretion of most drugs 
eliminated by this active transport system is also reduced. Another factor affecting active 
tubular secretion of drugs is that this is a transport-mediated process so that, with higher drug 
levels, the secretion reaches a limit leading to an increased elimination half-life. Also, 
competition between drugs for active secretion can reduce their excretion (see below : drug-
drug interactions). Both endogenous substances and drugs are secreted and reabsorbed by 
these transporters. Patients with renal failure may develop toxicity due to competition for 
these pathways of secretion due to endogenous substances and medications that compete for 
these transporters (11). A better insight into the molecular mechanisms and transporters 
governing renal drug elimination is required to better predict the in vivo kinetic profile of 
substrate drugs, especially in presence of CKD. 
 
 c) Tubular reabsorption 
 In healthy kidneys, the renal clearance of many drugs is slow because they are 
substantially reabsorbed from the distal portion of the nephron, despite glomerular filtration 
and active secretion (6). This is a passive process, which is, however, affected by several 
factors, including protein binding, medication lipophilicity, urine concentrating activities and 
pH. Only drugs in an uncharged (more lipid soluble form) state may freely cross cell 
membranes and thus the tubular barrier to be passively reabsorbed. Weak acids gain protons 
in an acidic environment and become uncharged whereas weak bases gain protons in an acidic 
environment and become charged (and vice versa). As expected, reductions in medication 
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reabsorption are observed in patients with CKD, resulting in increased urinary concentrations 
of renally eliminated medications, such as aspirin and lithium (6). 
  
 c) Renal metabolism 
 A factor of drug biotransformation that cannot be overlooked is the kidney as a site for 
drug metabolism. Normally, the kidneys have nearly 15% of the metabolic function of the liver, 
with most of the metabolic enzymes located in the renal cortex (15). Some drugs are more 
extensively metabolized via the kidney (6). Renal metabolism is obviously reduced in CKD. This 
results in increased parent compound concentrations, potentially increasing the prevalence of 
adverse effects. 
  
3) Drug-drug interactions in the kidney 
  Patients with CKD frequently require multiple pharmaceutical agents to manage both the 
underlying renal dysfunction and frequent comorbid disease states. Given the propensity for 
polypharmacy in this population, the potential for adverse events and drug-drug interactions is 
high (16). Many drugs are dependent on renal transporters for their ultimate urinary elimination 
(14). Combined use of drugs that interact with renal transporters may increase the risk for drug 
interactions. 
 Drug-drug interactions due to competitive inhibition of renal organic anion or cation 
secretion systems have been noticed clinically for a long time (17). Medications can interact with 
either organic anion (OAT) or cation (OCT) transporters in proximal tubular cells (11,14). In 
both cases, drug elimination is impaired.  A classical example is probenecid that inhibits renal 
secretion of other anionic drugs through inhibition of the organic anion transport system. Renal 
excretion of penicillin derivatives and various other drugs (e.g. cisplatin, ciprofloxacin, …) is 
also decreased by coadministration of probenecid. Similarly, nonsteroidal anti-inflammatory 
drugs may inhibit the renal excretion of methotrexate via specific transporters so that 
coadministration may result in severe methotrexate toxicity (bone marrow depression, renal 
insufficiency, hepatitis). Other drugs, such as cimetidine and trimethoprim, appear to be potent 
inhibitors of the renal tubular secretion of a number cationic drugs, which also results in adverse 
drug side effects (14). When coadministered with compounds that inhibit P-glycoprotein renal 
transport activity (e.g. quinidine, clarithromycin, ritonavir, …), tubular secretion of digoxin is 
markedly diminished, thereby leading to an increase in plasma digoxin concentrations and 
potential cardiac toxicity (14). The risk of severe adverse events due to such drug-drug 
interactions is even greater in patients with CKD. A better insight into the molecular mechanisms 
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governing renal drug elimination is likely to aid in the design or use of drugs with greater safety 
profiles (14).    
 
4) Drug dosing adjustments in kidney disease 
 Drug dosing in patients with CKD requires knowledge of the pharmacologic alterations 
that occur with renal dysfunction (see above). Drug dosing errors are common in patients with 
renal impairment and can cause adverse effects and poor outcomes (4,5). Physicians should pay 
careful attention when considering drug therapies with active or toxic metabolites that can 
accumulate and contribute to exaggerated pharmacologic effects or adverse drug reactions in 
patients with CKD. Dosages of drugs cleared renally should be adjusted based on the patient’s 
renal function, calculated as creatinine clearance or GFR. A common oversight in prescribing 
medications to patients with CKD is inherently to reduce the drug doses or prolong the dosing 
intervals at the initiation of therapy. Initial dosages should be determined using published 
guidelines and adjusted based on patient’s response (4). Serum drug concentrations should be 
used to monitor effectiveness and toxicity when appropriate. This is the case for many drugs 
such as digoxin, ciclosporin, aminoglycosides, … (6). 
 Dosing theories in the CKD population may concern both loading (initial) dose and 
maintenance dose (4,6). The purpose of a loading dose is to produce rapidly a therapeutic plasma 
concentration. In clinical practice, loading doses usually do not need to be adjusted in patients 
with CKD. Digoxin is one medication exception to this general rule. After the initiation of 
therapy with a loading dose, a maintenance dose is required to maintain steady-state plasma 
concentrations. Recommended methods for maintenance dosing adjustments are dose reductions, 
lengthening the dosing interval, or both. Dose reduction maintains more constant drug 
concentrations, but it is associated with a higher risk of toxicities if the dosing interval is 
inadequate to allow for drug elimination. Normal doses are maintained with the extended interval 
method, but the dosing interval is lengthened to allow time for drug elimination, before redosing. 
Lengthening the dosing interval has been associated with a lower risk of toxicities but a higher 
risk of subtherapeutic drug concentrations, especially toward the end of the dosing interval. 
Nevertheless, this expanded interval method generally corresponds well with CKD-induced 
delays in medication excretion, allowing more time for the drug to be eliminated before redosing. 
To calculate an extended dosing interval, one must calculate the patient’s creatinine clearance 
and know the normal dosing interval of the medication to be administered. Using the following 
equation, one can determine the appropriate dosing interval on a patient-by-patient basis : new 
expanded dosing interval = (normal creatinine clearance per the patient’s calculated creatinine 
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clearance) x the normal dosing interval (6). The method works particularly well with medications 
that have a broad therapeutic window and a long half-life. 
  
5. Extracorporeal removal of drugs 
 Drugs are eliminated to some degree by the various forms of dialysis, including 
hemodialysis, peritoneal dialysis, and continuous renal replacement therapies (11). However, 
extracorporeal removal of drugs is difficult to predict and influenced by various factors, among 
which molecular weight of drug, distribution volume of drug, drug solubility, protein binding, 
poor size and surface area of hemodialysis membrane, blood and dialysate flow rates, … Several 
drugs require dosing after hemodialysis. Guidelines are available in books on subject on drug 
prescribing in dialysis (18).  The difficulties related to extracorporeal removal of drugs will not 
be further covered as this topic is outside that of the present review dealing more specifically 
with medications in the kidney.   
 
6. Conclusions 
 Although optimization of the desired therapeutic outcomes are of paramount importance, 
additional therapeutic issues for patients with reduced renal function are the prevention or 
minimization of future acute or chronic nephrotoxic insults, as well as the severity and 
occurrence of adverse effects on other organ systems. Indeed, the incidence of adverse events is 
much higher in patients with CKD than in those without renal insufficiency. The general 
principles to enhance the safety of drug therapy in patients with CKD include knowledge of the 
pharmacokinetics, interactions and potential toxicities of the therapeutic agent, consideration of 
possible alternative therapies and individualization of drug dosing based on patient level of renal 
function. Some medications need to be avoided all together in CKD either because of lack of 
efficacy or more importantly risk of toxicity. Numerous other medications require appropriate 
dosing adjustments, either by reducing the individual dose, or lengthening the dosing interval, or 
both. It is important to understand how to appropriately prescribe medications to patients with 
various levels of acute renal failure and CKD, including those undergoing some form of renal 
replacement therapy. Application of the pharmacotherapeutic principles into clinical practice, 
especially appropriate drug dosing adjustments, will hopefully enhance the safety of these agents 
and optimize patient outcomes.    
 
References 
1. Brater DC. The pharmacological role of the kidney. Drugs. 1980; 19: 31-48. 
 
 
 - 9 -
2. Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis. 1986; 8: 7-
17. 
3. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Minimizing 
renal and extrarenal toxicity. Drug Saf. 1997; 16: 205-31. 
4. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am 
Fam Physician. 2007; 75: 1487-96. 
5. Anonymous. The patient, the drug and the kidney. Drug Ther Bull. 2006; 44: 89-95. 
6. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am. 2005; 
89: 649-87.  
7. Scheen AJ. Particularités de la pharmacothérapie chez le sujet âgé. Rev Med Liège. 1997; 
52: 201-4. 
8. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004; 2: 274-
302. 
9. Lam YW, Banerji S, Hatfield C, et al. Principles of drug administration in renal 
insufficiency. Clin Pharmacokinet. 1997; 32: 30-57. 
10. Aronoff G, Berns J, Brier M, et al. Drug prescribing in renal failure : dosing guidelines for 
adults. 4th edition. Philadelphia, USA: American College of Physicians, 1999. 
11. Perazella MA, Parikh C. Core curriculum in nephrology. Pharmacology. Am J Kidn Dis. 
2005; 46: 1129-39. 
12. Masereeuw R, Russel FG. Mechanisms and clinical implications of renal drug excretion. 
Drug Metab Rev. 2001; 33: 299-351. 
13. Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of 
assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003; 42: 1193-
211. 
14. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 
2004; 44: 137-66. 
15. Anders MW. Metabolism of drugs by the kidney. Kidney Int. 1980; 18: 636-47. 
16. Scheen AJ. Interactions médicamenteuses : de la théorie à la pratique. Rev Med Liège. 
2006; 61: 471-82. 
17. Li M, Anderson GD, Wang J. Drug-drug interactions involving membrane transporters in 
the human kidney. Expert Opin Drug Metab Toxicol. 2006; 2; 505-32. 
18. Aronoff GR, Brier ME. Prescribing drugs for dialysis patients. In : Henrich WL, ed. 
Principles and Practice of Dialysis (ed 3). Philadelphia, PA, Lippincott Williams & 
 
 
 - 10 -
Wilkins, 2004: 147-61. 
